Identification

Name
Oxycodone
Accession Number
DB00497  (APRD00387)
Type
Small Molecule
Groups
Approved, Illicit, Investigational
Description

Oxycodone is a semisynthetic derivative of codeine that acts as a narcotic analgesic more potent and addicting than codeine. An extended-release (ER) form of oxycodone (Xtampza ER) was approved for the management of daily, around-the-clock pain management in April, 2016.

Structure
Thumb
Synonyms
  • (-)-14-Hydroxydihydrocodeinone
  • 4,5-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one
  • 4,5alpha-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one
  • 4,5α-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one
  • Dihydro-14-hydroxycodeinone
  • Dihydrohydroxycodeinone
  • Dihydroxycodeinone
  • Oxicodona
  • Oxycodone
  • Oxycodonum
External IDs
IDS-NO-002 / N02AA05 / NSC-19043 / PF-00345439 / PTI-821
Product Ingredients
IngredientUNIICASInChI Key
Oxycodone hydrochlorideC1ENJ2TE6C124-90-3MUZQPDBAOYKNLO-RKXJKUSZSA-N
Oxycodone terephthalateM04XWV43UF124133-68-2BTEYIHUKHHAVAN-KDKWOIFOSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act Oxycodone CRTablet, extended release5 mgOralActavis Pharma Company2012-11-26Not applicableCanada
Act Oxycodone CRTablet, extended release20 mgOralActavis Pharma Company2012-11-26Not applicableCanada
Act Oxycodone CRTablet, extended release80 mgOralActavis Pharma Company2012-11-26Not applicableCanada
Act Oxycodone CRTablet, extended release10 mgOralActavis Pharma Company2012-11-26Not applicableCanada
Act Oxycodone CRTablet, extended release40 mgOralActavis Pharma Company2012-11-26Not applicableCanada
OxaydoTablet7.5 mg/1OralEgalet US Inc.2015-09-01Not applicableUs
OxaydoTablet7.5 mg/1OralLake Erie Medical DBA Quality Care Products LLC2015-09-012018-12-31Us
OxaydoTablet5 mg/1OralEgalet US Inc.2015-09-01Not applicableUs
OxaydoTablet5 mg/1OralLake Erie Medical DBA Quality Care Products LLC2015-09-012017-12-31Us
OxectaTablet5 mg/1OralPfizer Laboratories Div Pfizer Inc.2011-06-17Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-oxycodone CRTablet, extended release40 mgOralApotex Corporation2012-11-26Not applicableCanada
Apo-oxycodone CRTablet, extended release60 mgOralApotex Corporation2012-11-27Not applicableCanada
Apo-oxycodone CRTablet, extended release10.0 mgOralApotex Corporation2012-11-26Not applicableCanada
Apo-oxycodone CRTablet, extended release5.0 mgOralApotex Corporation2012-11-26Not applicableCanada
Apo-oxycodone CRTablet, extended release80.0 mgOralApotex Corporation2012-11-26Not applicableCanada
Apo-oxycodone CRTablet, extended release30 mgOralApotex Corporation2012-11-27Not applicableCanada
Apo-oxycodone CRTablet, extended release20.0 mgOralApotex Corporation2012-11-26Not applicableCanada
Apo-oxycodone CRTablet, extended release15 mgOralApotex Corporation2012-11-27Not applicableCanada
Oxycodone HClTablet15 mg/1OralDirectrx2016-02-22Not applicableUs
Oxycodone HClTablet30 mg/1OralDirectrx2016-02-22Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Apo-oxycodone/acetOxycodone hydrochloride (5 mg) + Acetaminophen (325 mg)TabletOralApotex Corporation2009-04-15Not applicableCanada
CombunoxOxycodone hydrochloride (5 mg/1) + Ibuprofen (400 mg/1)TabletOralFOREST PHARMACEUTICALS, INC.2004-11-262011-03-03Us
EndocetOxycodone hydrochloride (7.5 mg/1) + Acetaminophen (500 mg/1)TabletOralBlenheim Pharmacal, Inc.2008-10-082011-10-31Us
EndocetOxycodone hydrochloride (7.5 mg/1) + Acetaminophen (500 mg/1)TabletOralEndo Pharmaceuticals Inc. DBA Endo Generic Products2000-12-062009-08-19Us
EndocetOxycodone hydrochloride (2.5 mg/1) + Acetaminophen (325 mg/1)TabletOralPar Pharmaceutical2003-03-06Not applicableUs
EndocetOxycodone hydrochloride (10 mg/1) + Acetaminophen (650 mg/1)TabletOralBlenheim Pharmacal, Inc.2008-05-282011-10-31Us
EndocetOxycodone hydrochloride (5 mg) + Acetaminophen (325 mg)TabletOralBristol Myers Squibb1995-12-31Not applicableCanada
EndocetOxycodone hydrochloride (10 mg/1) + Acetaminophen (325 mg/1)TabletOralStat Rx USA2003-03-06Not applicableUs
EndocetOxycodone hydrochloride (5 mg/1) + Acetaminophen (325 mg/1)TabletOralLake Erie Medical Dba Quality Care Produts Llc2000-05-262015-12-31Us
EndocetOxycodone hydrochloride (5 mg/1) + Acetaminophen (325 mg/1)TabletOralBlenheim Pharmacal, Inc.2008-05-282011-09-30Us
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Oxycodone HydrochlorideOxycodone hydrochloride (20 mg/1mL)Solution, concentrateOralMallinckrodt2009-06-022011-10-31Us
Oxycodone HydrochlorideOxycodone hydrochloride (20 mg/1mL)Solution, concentrateOralPhysicians Total Care, Inc.2006-01-012011-07-31Us
Oxycodone HydrochlorideOxycodone hydrochloride (20 mg/1mL)Solution, concentrateOral8282696752013-09-232013-09-23Us
Oxycodone HydrochlorideOxycodone hydrochloride (5 mg/5mL)SolutionOralMallinckrodt2009-06-022011-10-31Us
Oxycodone HydrochlorideOxycodone hydrochloride (5 mg/1)CapsuleOralPhysicians Total Care, Inc.2006-05-082013-01-11Us
Oxycodone HydrochlorideOxycodone hydrochloride (20 mg/1mL)Solution, concentrateOralMallinckrodt2009-06-022011-10-31Us
Oxycodone Hydrochloride Immediate-releaseOxycodone hydrochloride (5 mg/1)CapsuleOralMallinckrodt2009-06-182012-07-31Us
RoxicodoneOxycodone hydrochloride (5 mg/5mL)SolutionOralXanodyne Pharmaceuticals2009-05-152010-12-16Us
RoxicodoneOxycodone hydrochloride (20 mg/1mL)ConcentrateOralXanodyne Pharmaceuticals2009-05-152010-12-16Us
International/Other Brands
Oxanest / OxyIR
Categories
UNII
CD35PMG570
CAS number
76-42-6
Weight
Average: 315.3636
Monoisotopic: 315.147058165
Chemical Formula
C18H21NO4
InChI Key
BRUQQQPBMZOVGD-XFKAJCMBSA-N
InChI
InChI=1S/C18H21NO4/c1-19-8-7-17-14-10-3-4-12(22-2)15(14)23-16(17)11(20)5-6-18(17,21)13(19)9-10/h3-4,13,16,21H,5-9H2,1-2H3/t13-,16+,17+,18-/m1/s1
IUPAC Name
(1S,5R,13R,17S)-17-hydroxy-10-methoxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0¹,¹³.0⁵,¹⁷.0⁷,¹⁸]octadeca-7(18),8,10-trien-14-one
SMILES
[H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1(O)CCC2=O

Pharmacology

Indication

For the treatment of diarrhoea, pulmonary oedema and for the relief of moderate to moderately severe pain.

Associated Conditions
Pharmacodynamics

Oxycodone, a semisynthetic opiate agonist derived from the opioid alkaloid, thebaine, is similar to other phenanthrene derivatives such as hydrocodone and morphine. Oxycodone is available in combination with aspirin or acetaminophen to control pain and restless leg and Tourette syndromes.

Mechanism of action

Oxycodone acts as a weak agonist at mu, kappa, and delta opioid receptors within the central nervous system (CNS). Oxycodone primarily affects mu-type opioid receptors, which are coupled with G-protein receptors and function as modulators, both positive and negative, of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine, and noradrenaline is inhibited. Opioids such as oxycodone also inhibit the release of vasopressin, somatostatin, insulin, and glucagon. Opioids close N-type voltage-operated calcium channels (kappa-receptor agonist) and open calcium-dependent inwardly rectifying potassium channels (mu and delta receptor agonist). This results in hyperpolarization and reduced neuronal excitability.

TargetActionsOrganism
AMu-type opioid receptor
agonist
Human
AKappa-type opioid receptor
agonist
Human
ADelta-type opioid receptor
agonist
Human
UKappa-type opioid receptor 2b
agonist
Human
Ualpha1-acid glycoprotein
binder
Human
Absorption

Well absorbed with an oral bioavailability of 60% to 87%

Volume of distribution
  • 2.6 L/kg
Protein binding

45%

Metabolism

Hepatic

Route of elimination

Oxycodone and its metabolites are excreted primarily via the kidney.

Half life

4.5 hours

Clearance
  • 0.8 L/min [adults]
Toxicity

Symptoms of overdose include respiratory depression, somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, constricted pupils, bradycardia, hypotension, and death.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Oxycodone Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(R)-warfarinThe metabolism of (R)-warfarin can be decreased when combined with Oxycodone.
(S)-WarfarinThe metabolism of (S)-Warfarin can be decreased when combined with Oxycodone.
2,5-Dimethoxy-4-ethylamphetamineThe risk or severity of serotonin syndrome can be increased when Oxycodone is combined with 2,5-Dimethoxy-4-ethylamphetamine.
2,5-Dimethoxy-4-ethylthioamphetamineThe risk or severity of serotonin syndrome can be increased when Oxycodone is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
3,4-MethylenedioxyamphetamineThe risk or severity of serotonin syndrome can be increased when Oxycodone is combined with 3,4-Methylenedioxyamphetamine.
3,5-diiodothyropropionic acidThe metabolism of 3,5-diiodothyropropionic acid can be decreased when combined with Oxycodone.
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of serotonin syndrome can be increased when Oxycodone is combined with 4-Bromo-2,5-dimethoxyamphetamine.
4-hydroxycoumarinThe metabolism of 4-hydroxycoumarin can be decreased when combined with Oxycodone.
4-MethoxyamphetamineThe risk or severity of adverse effects can be increased when Oxycodone is combined with 4-Methoxyamphetamine.
5-androstenedioneThe metabolism of 5-androstenedione can be decreased when combined with Oxycodone.
Food Interactions
  • Take without regard to meals. Avoid alcohol.

References

Synthesis Reference

Bao-Shan Huang, Yansong Lu, Ben-Yi Ji, Aris P Christodoulou, "Preparation of oxycodone from codeine." U.S. Patent US6008355, issued March, 1990.

US6008355
General References
  1. Ordonez Gallego A, Gonzalez Baron M, Espinosa Arranz E: Oxycodone: a pharmacological and clinical review. Clin Transl Oncol. 2007 May;9(5):298-307. [PubMed:17525040]
  2. Riley J, Eisenberg E, Muller-Schwefe G, Drewes AM, Arendt-Nielsen L: Oxycodone: a review of its use in the management of pain. Curr Med Res Opin. 2008 Jan;24(1):175-92. [PubMed:18039433]
External Links
Human Metabolome Database
HMDB0014640
KEGG Drug
D05312
KEGG Compound
C08018
PubChem Compound
5284603
PubChem Substance
46508908
ChemSpider
4447649
BindingDB
50370595
ChEBI
7852
ChEMBL
CHEMBL656
Therapeutic Targets Database
DAP000283
PharmGKB
PA450741
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Oxycodone
ATC Codes
N02AA55 — Oxycodone, combinationsN02AA05 — Oxycodone
AHFS Codes
  • 28:08.08 — Opiate Agonists
FDA label
Download (689 KB)
MSDS
Download (50.5 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingBasic SciencePrescription Drug Abuse (Not Dependent)1
0RecruitingSupportive CareMetastatic Malignant Neoplasm / Neoplasms, Malignant / Pain NOS1
0RecruitingTreatmentLocally Advanced Head and Neck Cancer1
0RecruitingTreatmentUrologic Diseases1
1CompletedNot AvailableHealthy Volunteers14
1CompletedNot AvailableOpioid Analgesia1
1CompletedNot AvailablePain NOS1
1CompletedBasic ScienceAnalgesia / Narcotic Abuse / Opioid-Related Disorders / Pain, Acute / Pain, Chronic1
1CompletedBasic ScienceHealthy Volunteers11
1CompletedBasic ScienceManagement of Moderate to Severe Pain1
1CompletedBasic ScienceOpioid Users1
1CompletedBasic SciencePain NOS2
1CompletedOtherOpioid Abuse Nondependent1
1CompletedOtherOsteoarthritis Thumbs1
1CompletedOtherPain, Chronic3
1CompletedTreatmentHealthy Volunteers3
1CompletedTreatmentPain NOS2
1Not Yet RecruitingBasic SciencePain NOS / Substance Abuse1
1RecruitingOtherPain, Chronic1
1RecruitingTreatmentColorectal Cancers1
1, 2CompletedTreatmentPain, Fracture, Sprain1
1, 2RecruitingTreatmentAdenotonsillectomy / Analgesia, Postoperative / Opioids Use1
2Active Not RecruitingTreatmentTonsillectomy1
2CompletedBasic ScienceOpioid-Related Disorders / Substance-Related Disorders1
2CompletedSupportive CareNutrition Disorders / Quality of Life1
2CompletedSupportive CarePain NOS1
2CompletedTreatmentDental Pain1
2CompletedTreatmentHeroin Dependence / Opioid-Related Disorders / Substance-Related Disorders1
2CompletedTreatmentKnee Osteoarthritis (Knee OA)2
2CompletedTreatmentMalignancies / Occasional Constipation / Pain NOS1
2CompletedTreatmentMalignancies / Pain NOS1
2CompletedTreatmentOpioid-Related Disorders1
2CompletedTreatmentPain, Acute1
2CompletedTreatmentPostoperative pain3
2Not Yet RecruitingSupportive CareCarpal Tunnel Syndrome (CTS) / Cystic tumour of the ganglia / De Quervain's Disease / Dupuytren's Contracture of the Hand (Viking's Disease) / Trigger Digit1
2RecruitingBasic ScienceOpioid Abuse / Opioid-use Disorder1
2RecruitingPreventionPain, Neuropathic1
2RecruitingTreatmentGeneral Surgery1
2RecruitingTreatmentOpioid-Related Disorders / Opioids Use / Rib Fractures1
2RecruitingTreatmentOpioid-use Disorder1
2RecruitingTreatmentPain Management1
2RecruitingTreatmentPainful musculoskeletal conditions1
2TerminatedTreatmentOsteoarthritis (OA)1
2TerminatedTreatmentToothache1
2, 3CompletedTreatmentMalignant Pain / Non-malignant Pain1
2, 3RecruitingTreatmentChronic Rhinosinusitis (Diagnosis)1
3Active Not RecruitingTreatmentBrachial Plexus Block / Postoperative pain1
3Active Not RecruitingTreatmentGynecologic Cancers / Malignant Neoplasms of Female Genital Organs1
3CompletedNot AvailableSubjects With Moderate to Severe, Chronic Nonmalignant Pain1
3CompletedNot AvailableWithdrawal Symptoms1
3CompletedBasic ScienceBack Pain Lower Back1
3CompletedSupportive CareAnalgesia After ED Discharge for Extremity Injuries1
3CompletedSupportive CareChronic Noncancer Pain1
3CompletedSupportive CarePain NOS1
3CompletedTreatmentAnalgesia / Back Pain Lower Back / Pain, Chronic1
3CompletedTreatmentArthritis / Joint Diseases / Osteoarthritis (OA)1
3CompletedTreatmentBack Pain1
3CompletedTreatmentBack Pain Lower Back2
3CompletedTreatmentBack Pain Lower Back / Knee Osteoarthritis (Knee OA) / Osteoarthritis, Hip / Pain NOS1
3CompletedTreatmentBack Pain / Back Pain Lower Back / Back Pain With Radiation / Pain NOS1
3CompletedTreatmentArthralgia/joint pain / Bunions / Hallux Valgus / Pain NOS1
3CompletedTreatmentKnee Osteoarthritis (Knee OA) / Pain NOS1
3CompletedTreatmentMalignancies1
3CompletedTreatmentMalignancies / Pain NOS1
3CompletedTreatmentModerate to Severe Postoperative Pain1
3CompletedTreatmentOpioids Use / Pain, Chronic1
3CompletedTreatmentOther Acute Postoperative Pain1
3CompletedTreatmentPain NOS7
3CompletedTreatmentPain, Chronic1
3CompletedTreatmentPost-Operative Nausea and Vomiting (PONV) / Postoperative pain1
3CompletedTreatmentPostoperative pain5
3CompletedTreatmentPruritus1
3CompletedTreatmentRenal Stones1
3Not Yet RecruitingTreatmentPain, Chronic1
3RecruitingSupportive CareBreast - Female1
3RecruitingSupportive CareCalcium Nephrolithiasis1
3RecruitingSupportive CareMalignant Head and Neck Neoplasm / Mucositis / Radiation-Induced Disorder1
3RecruitingTreatmentAbortion in First Trimester1
3RecruitingTreatmentBack Pain / Cervical Pain1
3RecruitingTreatmentJoint Diseases1
3RecruitingTreatmentOpioids Use / Shoulder Pain1
3TerminatedTreatmentArthroplasty1
3TerminatedTreatmentOsteoarthritis (OA)1
3TerminatedTreatmentSevere Caner Pain1
3Unknown StatusSupportive CareMalignancies / Pain NOS1
3Unknown StatusTreatmentBreakthrough Cancer Pain1
4Active Not RecruitingTreatmentCritical Illness1
4Active Not RecruitingTreatmentNarcotic Abuse / Opiate Addiction / Opioid-Related Disorders / Substance Abuse1
4Active Not RecruitingTreatmentPostoperative pain1
4CompletedNot AvailablePain NOS1
4CompletedBasic ScienceHealthy Volunteers1
4CompletedBasic ScienceHealthy, no Evidence of Disease1
4CompletedBasic ScienceSubstance-Related Disorders1
4CompletedDiagnosticPain NOS1
4CompletedSupportive CareEffects of 2 Mu-opiates on Gastrointestinal Transit1
4CompletedSupportive CareMalignancies1
4CompletedSupportive CarePain NOS / Unspecified Adult Solid Tumor, Protocol Specific1
4CompletedSupportive CarePain, Cancer1
4CompletedSupportive CarePain, Chronic1
4CompletedSupportive CareSpinal Disorders / Spinal Disorders Related Pain1
4CompletedTreatmentAcute Low Back Pain1
4CompletedTreatmentArthroplasty, Replacement, Hip1
4CompletedTreatmentBack Pain Lower Back Chronic / Depression / Feeling Anxious / Intervertebral Disc Degeneration1
4CompletedTreatmentBack Pain / Back Pain Lower Back / Pain, Neuropathic1
4CompletedTreatmentBack Pain / Osteoarthritis (OA)1
4CompletedTreatmentBenign muscle neoplasm / Hysterectomy / Opioids / Postoperative pain1
4CompletedTreatmentDisorder of Knee1
4CompletedTreatmentEpidural Analgesia / Oral Oxycodone With/Without Naloxone / Postoperative Pain Management / Radical Cystectomy / Return of the Bowel Function1
4CompletedTreatmentFlank Pain / Urinary Bladder, Overactive1
4CompletedTreatmentFracture Bone1
4CompletedTreatmentHealthy Volunteers1
4CompletedTreatmentHeart; Dysfunction Postoperative, Cardiac Surgery1
4CompletedTreatmentImpaired Renal Function / Myocardial Infarction / Postoperative pain1
4CompletedTreatmentMAB / Pain NOS1
4CompletedTreatmentMalignancies2
4CompletedTreatmentMalignancies / Pain, Cancer1
4CompletedTreatmentNarcotic Use / Nausea / Occasional Constipation / Pain NOS1
4CompletedTreatmentNausea1
4CompletedTreatmentOccasional Constipation1
4CompletedTreatmentOocyte Retrieval / Postoperative pain1
4CompletedTreatmentOpioid Related Disorders / Postoperative pain1
4CompletedTreatmentOsteoarthritis (OA) / Pain, Chronic1
4CompletedTreatmentPain NOS2
4CompletedTreatmentPain, Acute1
4CompletedTreatmentPost Operative Pain2
4CompletedTreatmentPostcraniotomy Pain1
4CompletedTreatmentPostoperative pain3
4CompletedTreatmentUnilateral Knee Arthroplasty1
4Not Yet RecruitingTreatmentAnalgesia, Patient-Controlled1
4Not Yet RecruitingTreatmentDistal Radius Fractures / Metacarpal Fractures / Pain Management1
4Not Yet RecruitingTreatmentOxycodone / Pharmacogenomics / Pharmacokinetics1
4Not Yet RecruitingTreatmentPain NOS2
4Not Yet RecruitingTreatmentPostoperative pain2
4Not Yet RecruitingTreatmentPostoperative pain / Renal Stones1
4Not Yet RecruitingTreatmentSupracondylar Humerus Fractures1
4RecruitingBasic ScienceChronic Kidney Disease (CKD)1
4RecruitingOtherPediatric Surgical Patient1
4RecruitingSupportive CareDeglutition / Opioids Use / Pain, Chronic1
4RecruitingSupportive CareImpaired Renal Function / Pain NOS / Terminal Illness1
4RecruitingSupportive CareScoliosis / Spondylolisthesis1
4RecruitingTreatmentAbortion Second Trimester1
4RecruitingTreatmentAnalgesics, Antipyretics, and Antirheumatics Causing Adverse Effects in Therapeutic Use / Opioids Use / Pain Uterus / Pain, Acute / Postoperative pain / Visceral Pain1
4RecruitingTreatmentBody Weight Changes / Post-Operative Nausea and Vomiting (PONV) / Postoperative Hemorrhages / Postoperative pain1
4RecruitingTreatmentDiseases of Mitral Valve / Postoperative pain2
4RecruitingTreatmentHip Arthroscopy1
4RecruitingTreatmentInguinal Hernias / Postoperative pain1
4RecruitingTreatmentLabour Pain1
4RecruitingTreatmentOccasional Constipation / Postoperative pain1
4RecruitingTreatmentOral Sedation and Cervical Dilator Pain1
4RecruitingTreatmentPain Management1
4RecruitingTreatmentPain NOS3
4RecruitingTreatmentPain, Acute1
4RecruitingTreatmentPostoperative pain2
4RecruitingTreatmentSleep Apnea Syndrome1
4SuspendedTreatmentPain, Chronic1
4TerminatedNot AvailablePeripheral Neuropathy1
4TerminatedTreatmentAnesthesia Recovery Period / Postoperative pain1
4TerminatedTreatmentDisseminated Sclerosis / Pain, Chronic / Pain, Neuropathic1
4TerminatedTreatmentPain, Chronic1
4Unknown StatusNot AvailableOpioid Induced Constipation (OIC) / Postoperative pain1
4Unknown StatusTreatmentBack Pain Lower Back1
4Unknown StatusTreatmentElective Laproscopic Bilateral Inguinal Hernia / Elective Laproscopic Cholecystectomy1
4Unknown StatusTreatmentPost Operative Pain1
4WithdrawnTreatmentPain, Chronic1
4WithdrawnTreatmentPost Operative Pain Control1
Not AvailableActive Not RecruitingNot AvailableAAT Deficiency / AATD / Alpha-1 Antitrypsin Deficiency / Fibrosis, Liver1
Not AvailableActive Not RecruitingTreatmentFlail Chest / General Surgery / Rib Fractures / Traumas1
Not AvailableCompletedNot AvailableBreakthrough Cancer Pain / Pain, Cancer / Pain, Neuropathic / Tumors1
Not AvailableCompletedNot AvailableHealthy Volunteers1
Not AvailableCompletedNot AvailablePain NOS1
Not AvailableCompletedNot AvailableSevere Pain1
Not AvailableCompletedNot AvailableSevere, Chronic Pain1
Not AvailableCompletedNot AvailableSubstance Abuse Detection1
Not AvailableCompletedBasic ScienceNarcotic Abuse1
Not AvailableCompletedPreventionCoughing Responses at Tracheal Extubation1
Not AvailableCompletedPreventionPost-Operative Nausea and Vomiting (PONV)1
Not AvailableCompletedSupportive CareHead and Neck Squamous Cell Carcinoma (HNSCC) / Pain NOS / Vesicular Stomatitis1
Not AvailableCompletedTreatmentDrug Drug Interaction (DDI)1
Not AvailableCompletedTreatmentElbow Fractures1
Not AvailableCompletedTreatmentHip Fracture Surgery / Post Operative Pain Control1
Not AvailableCompletedTreatmentLabour Pain1
Not AvailableNot Yet RecruitingNot AvailableOxycontin1
Not AvailableNot Yet RecruitingTreatmentHerpes Zoster / Post-Herpetic Neuralgia (PHN)1
Not AvailableNot Yet RecruitingTreatmentPeripheral Arterial Disease (PAD)1
Not AvailableRecruitingNot AvailableMultimodal Analgesia / Nonsteroidal Anti-inflammatory Drugs1
Not AvailableRecruitingSupportive CareStage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8 / Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v81
Not AvailableRecruitingTreatmentChronic Pain, Postoperative / Postoperative pain1
Not AvailableRecruitingTreatmentGeneral Surgery / Pain NOS / Rib Fractures / Traumas1
Not AvailableRecruitingTreatmentHip Pain Chronic1
Not AvailableSuspendedTreatmentLaceration / Pain NOS1
Not AvailableTerminatedNot AvailableOsteoarthritis (OA)1
Not AvailableTerminatedSupportive CareBrain and Central Nervous System Tumors / Chronic Myeloproliferative Disorders / Leukemias / Lymphoproliferative Disorders / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms / Pain NOS / Precancerous Conditions / Unspecified Adult Solid Tumor, Protocol Specific1
Not AvailableTerminatedTreatmentAnaesthesia therapy1
Not AvailableUnknown StatusNot AvailableAnalgesic Response1
Not AvailableWithdrawnSupportive CareBack Pain Lower Back1

Pharmacoeconomics

Manufacturers
  • Mallinckrodt inc
  • Purdue pharma lp
  • Roxane laboratories inc
  • Actavis totowa llc
  • Avanthi inc
  • Corepharma llc
  • Kv pharmaceutical co
  • Sun pharmaceutical industries inc
  • Tyco healthcare mallinckrodt
  • Vintage pharmaceuticals inc
  • Xanodyne pharmaceuticals inc
  • Endo Pharmaceuticals
Packagers
  • 4uOrtho LLC
  • Actavis Group
  • Amerisource Health Services Corp.
  • Amneal Pharmaceuticals
  • Apotex Inc.
  • Apotheca Inc.
  • Athlon Pharmaceuticals Inc.
  • Atley Pharmaceuticals
  • Barr Pharmaceuticals
  • Blenheim Pharmacal
  • Bristol-Myers Squibb Co.
  • Bryant Ranch Prepack
  • Caraco Pharmaceutical Labs
  • Cardinal Health
  • Chattem Chemicals Inc.
  • Cody Laboratories Inc.
  • Core Pharmaceuticals
  • Corepharma LLC
  • D.M. Graham Laboratories Inc.
  • DAVA Pharmaceuticals
  • Direct Dispensing Inc.
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Dorx LLC
  • DSM Corp.
  • Endo Pharmaceuticals Inc.
  • Endogen
  • Ethex Corp.
  • Forest Pharmaceuticals
  • Glenmark Generics Ltd.
  • Global Pharmaceuticals
  • Impax Laboratories Inc.
  • Ivax Pharmaceuticals
  • Janssen-Ortho Inc.
  • KV Pharmaceutical Co.
  • KVK-Tech Inc.
  • Lake Erie Medical and Surgical Supply
  • Lannett Co. Inc.
  • Lehigh Valley Technologies Inc.
  • Major Pharmaceuticals
  • Mallinckrodt Inc.
  • Mckesson Corp.
  • Metrics Inc.
  • Midlothian Labs
  • Mikart Inc.
  • Mylan
  • Novartis AG
  • Nucare Pharmaceuticals Inc.
  • Ortho-McNeil-Janssen Pharmaceuticals Inc.
  • P F Laboratories Inc.
  • Palmetto Pharmaceuticals Inc.
  • PD-Rx Pharmaceuticals Inc.
  • Physicians Total Care Inc.
  • Purdue Pharma LP
  • Qualitest
  • Quality Care
  • Ranbaxy Laboratories
  • Rebel Distributors Corp.
  • Redpharm Drug
  • Rhodes Pharmaceutical LP
  • Roxane Labs
  • St Mary's Medical Park Pharmacy
  • Stat Rx Usa
  • Sun Pharmaceutical Industries Ltd.
  • Superior Pharmeceuticals
  • Teva Pharmaceutical Industries Ltd.
  • Ther-Rx Corp.
  • Victory Pharma
  • Vindex Pharmaceuticals Inc.
  • Vintage Pharmaceuticals Inc.
  • Vistapharm Inc.
  • Watson Pharmaceuticals
  • WraSer Pharmaceuticals
  • Xanodyne Pharmaceuticals Inc.
Dosage forms
FormRouteStrength
Tablet, extended releaseOral5 mg
Tablet, extended releaseOral10.0 mg
Tablet, extended releaseOral20.0 mg
Tablet, extended releaseOral40 mg
Tablet, extended releaseOral5.0 mg
Tablet, extended releaseOral80.0 mg
TabletOral7.5 mg/1
Tablet, multilayer, extended releaseOral20 mg
CapsuleOral
Capsule, gelatin coatedOral
Tablet, coatedOral
CapsuleOral5 mg/1
SolutionOral100 mg/5mL
SolutionOral20 mg/1mL
Solution, concentrateOral20 mg/1mL
TabletOral10 mg/1
TabletOral15 mg/1
TabletOral20 mg/1
TabletOral30 mg/1
TabletOral40 mg/1
TabletOral5 mg/1
TabletOral80 mg/1
Tablet, film coated, extended releaseOral10 mg/1
Tablet, film coated, extended releaseOral20 mg/1
Tablet, film coated, extended releaseOral40 mg/1
Tablet, film coated, extended releaseOral80 mg/1
Tablet, film coatedOral
Tablet, extended releaseOral10 mg/1
Tablet, extended releaseOral20 mg/1
Tablet, extended releaseOral40 mg/1
Tablet, extended releaseOral80 mg/1
Tablet, film coated, extended releaseOral15 mg/1
Tablet, film coated, extended releaseOral160 mg/1
Tablet, film coated, extended releaseOral30 mg/1
Tablet, film coated, extended releaseOral60 mg/1
Tablet, extended releaseOral15 mg
Tablet, extended releaseOral30 mg
Tablet, extended releaseOral60 mg
Tablet, extended releaseOral10 mg
Tablet, extended releaseOral20 mg
Tablet, extended releaseOral80 mg
SolutionOral
ConcentrateOral20 mg/1mL
SolutionOral5 mg/5mL
Tablet, coatedOral15 mg/1
Tablet, coatedOral30 mg/1
Tablet, coatedOral5 mg/1
TabletOral
TabletOral20 mg
SuppositoryRectal10 mg
TabletOral10 mg
SuppositoryRectal20 mg
TabletOral5 mg
Tablet, extended releaseOral
Capsule, extended releaseOral
Capsule, extended releaseOral13.5 mg/1
Capsule, extended releaseOral18 mg/1
Capsule, extended releaseOral27 mg/1
Capsule, extended releaseOral36 mg/1
Capsule, extended releaseOral9 mg/1
Prices
Unit descriptionCostUnit
Oxycodone hcl powder53.64USD g
Roxicodone 5 mg/5ml Solution 500ml Bottle53.0USD bottle
Roxicodone 20 mg/ml Concentrate 30ml Bottle46.99USD bottle
OxyCODONE HCl 20 mg/ml Concentrate 30ml Bottle33.99USD bottle
Oxycontin 60 mg tablet17.08USD tablet
OxyCONTIN 80 mg 12 Hour tablet14.36USD tablet
Oxycontin 20 mg tablet11.87USD tablet
Oxycontin 80 mg tablet11.53USD tablet
OxyCONTIN 60 mg 12 Hour tablet10.57USD tablet
Oxycontin 40 mg tablet9.45USD tablet
OxyCODONE HCl 80 mg 12 Hour tablet8.33USD tablet
OxyCONTIN 40 mg 12 Hour tablet7.68USD tablet
Oxycontin 10 mg tablet6.89USD tablet
Oxycontin 30 mg tablet6.59USD tablet
OxyCONTIN 30 mg 12 Hour tablet5.8USD tablet
Roxicodone 30 mg tablet5.19USD tablet
Oxycontin 80 mg Sustained-Release Tablet4.69USD tablet
OxyCODONE HCl 40 mg 12 Hour tablet4.38USD tablet
OxyCONTIN 20 mg 12 Hour tablet4.27USD tablet
Oxycontin 60 mg Sustained-Release Tablet3.55USD tablet
Oxycontin 15 mg tablet3.22USD tablet
Supeudol 20 mg Suppository2.95USD suppository
Roxicodone 15 mg tablet2.83USD tablet
Oxycodone hcl 10 mg tablet2.82USD tablet
Endocet 10-650 mg tablet2.7USD tablet
Endocet 7.5-325 mg tablet2.54USD tablet
Oxycontin 40 mg Sustained-Release Tablet2.54USD tablet
OxyCONTIN 10 mg 12 Hour tablet2.53USD tablet
Supeudol 10 mg Suppository2.33USD suppository
Roxicodone intensol 20 mg/ml2.3USD ml
Endocet 7.5-500 mg tablet2.22USD tablet
Oxycodone-apap 2.5-325 mg tablet2.05USD tablet
Percodan 4.5-0.38-325 mg tablet1.98USD tablet
Oxycontin 30 mg Sustained-Release Tablet1.96USD tablet
Endocet 10-325 mg tablet1.87USD tablet
Endocet 5-325 tablet1.82USD tablet
Percodan tablet1.62USD tablet
Oxycontin 20 mg Sustained-Release Tablet1.46USD tablet
Dazidox 20 mg tablet1.44USD tablet
Oxycodone hcl 30 mg tablet1.41USD tablet
Oxycontin 15 mg Sustained-Release Tablet1.19USD tablet
Endodan 4.83-325 mg tablet1.18USD tablet
Oxycodone hcl 20 mg tablet1.1USD tablet
Oxycontin 10 mg Sustained-Release Tablet0.98USD tablet
Oxycodone hcl 15 mg tablet0.9USD tablet
Oxycodone hcl 5 mg tablet0.81USD tablet
Dazidox 10 mg tablet0.75USD tablet
Oxy-Ir 20 mg Tablet0.74USD tablet
OxyCODONE HCl 5 mg capsule0.71USD capsule
Oxycontin 5 mg Sustained-Release Tablet0.7USD tablet
Endocet 5-325 mg tablet0.6USD tablet
Roxicodone 5 mg tablet0.56USD tablet
Oxyir 5 mg capsule0.52USD capsule
Oxy-Ir 10 mg Tablet0.43USD tablet
Pms-Oxycodone 20 mg Tablet0.42USD tablet
Supeudol 20 mg Tablet0.42USD tablet
Oxycodone 5 mg tablet0.36USD tablet
Pms-Oxycodone 10 mg Tablet0.24USD tablet
Supeudol 10 mg Tablet0.24USD tablet
Pms-Oxycodone 5 mg Tablet0.14USD tablet
Supeudol 5 mg Tablet0.14USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5508042No1996-04-162013-04-16Us
CA2098738No1999-08-172012-11-25Canada
US9205082No2015-12-082022-05-10Us
US6488962No2002-12-032020-06-20Us
US8309060No2012-11-132023-11-20Us
US8808741No2014-08-192027-08-24Us
US9073933No2015-07-072025-03-30Us
US9060976No2015-06-232022-08-06Us
US6488963No2002-12-032017-06-24Us
US7674800No2010-03-092025-03-30Us
US7683072No2010-03-232025-03-30Us
US8337888No2012-12-252022-08-06Us
US7776314No2010-08-172025-04-19Us
US8894988No2014-11-252027-08-24Us
US7674799No2010-03-092025-03-30Us
US8114383No2012-02-142024-10-10Us
US8894987No2014-11-252030-03-29Us
US8685443No2014-04-012025-07-03Us
US7815934No2010-10-192027-12-12Us
US9168252No2015-10-272022-05-10Us
US9161937No2015-10-202022-05-10Us
US8969369No2015-03-032022-05-10Us
US9084729No2015-07-212022-05-10Us
US9283216No2016-03-152022-05-10Us
US9056051No2015-06-162022-05-10Us
US8846090No2014-09-302023-04-04Us
US6277384No2001-08-212018-12-22Us
US8822487No2014-09-022018-12-22Us
US8673355No2014-03-182018-12-22Us
US6696066No2004-02-242018-12-22Us
US8846091No2014-09-302023-04-04Us
US8372432No2013-02-122029-03-11Us
US8668929No2014-03-112029-03-11Us
US8377453No2013-02-192029-11-19Us
US7976870No2011-07-122027-06-01Us
US8741885No2014-06-032032-05-16Us
US8992975No2015-03-312032-05-16Us
US8597681No2013-12-032030-12-21Us
US8980319No2015-03-172030-12-21Us
US8394408No2013-03-122029-03-11Us
US9050335No2015-06-092032-05-16Us
US8658631No2014-02-252032-05-16Us
US7510726No2009-03-312023-11-26Us
US8409616No2013-04-022023-11-26Us
US7201920No2007-04-102025-03-16Us
US8637540No2014-01-282023-11-26Us
US7981439No2011-07-192023-11-26Us
US7955619No2011-06-072028-08-12Us
US9492389No2016-11-152027-08-24Us
US9522919No2016-12-202025-03-30Us
US9492392No2016-11-152027-08-24Us
US9492391No2016-11-152027-08-24Us
US9492393No2016-11-152027-08-24Us
US9345701No2016-05-242022-05-10Us
US9511066No2016-12-062022-05-10Us
US9555000No2017-01-312023-04-04Us
US9474750No2016-10-252018-12-22Us
US9283221No2016-03-152022-05-10Us
US9468636No2016-10-182032-05-16Us
US9492443No2016-11-152024-05-26Us
US9044398No2015-06-022023-07-07Us
US7771707No2010-08-102025-03-24Us
US9248195No2016-02-022023-07-07Us
US8557291No2013-10-152025-03-21Us
US8449909No2013-05-282025-03-24Us
US7399488No2008-07-152025-03-24Us
US9592200No2017-03-142023-07-07Us
US9682075No2017-06-202030-12-10Us
US8758813No2014-06-242025-06-10Us
US8840928No2014-09-232023-07-07Us
US9675610No2017-06-132023-06-16Us
US9737530No2017-08-222036-09-02Us
US9763933No2017-09-192027-08-24Us
US9770416No2017-09-262027-08-24Us
US9775808No2017-10-032027-08-24Us
US9763883No2017-09-192023-07-07Us
US9907793No2018-03-062023-04-04Us
US9968598No2018-05-152036-09-02Us
US10004729No2010-12-102030-12-10Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)219 °CPhysProp
water solubility100 mg/mlNot Available
logP0.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility5.59 mg/mLALOGPS
logP1.04ALOGPS
logP1.03ChemAxon
logS-1.8ALOGPS
pKa (Strongest Acidic)13.56ChemAxon
pKa (Strongest Basic)8.21ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area59 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity84.04 m3·mol-1ChemAxon
Polarizability32.8 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9924
Blood Brain Barrier+0.9885
Caco-2 permeable+0.7774
P-glycoprotein substrateSubstrate0.8996
P-glycoprotein inhibitor IInhibitor0.539
P-glycoprotein inhibitor IINon-inhibitor0.9122
Renal organic cation transporterNon-inhibitor0.5413
CYP450 2C9 substrateNon-substrate0.822
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.7796
CYP450 1A2 substrateNon-inhibitor0.9327
CYP450 2C9 inhibitorNon-inhibitor0.9431
CYP450 2D6 inhibitorNon-inhibitor0.5131
CYP450 2C19 inhibitorNon-inhibitor0.882
CYP450 3A4 inhibitorNon-inhibitor0.8714
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9691
Ames testNon AMES toxic0.7337
CarcinogenicityNon-carcinogens0.9557
BiodegradationNot ready biodegradable0.9746
Rat acute toxicity3.0638 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9402
hERG inhibition (predictor II)Non-inhibitor0.9279
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-014i-6975000000-ecd49efa58246c903e23
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-014i-0009000000-d55749fa4d1f47ce2244
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-00kb-0095000000-83c78e9e15857145cc78
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0002-0090000000-ad908ecfa38c7efce138
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0006-0390000000-88d302b8770cb7121937
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-03fu-0790000000-4af50b834ee854320001

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenanthrenes and derivatives. These are polycyclic compounds containing a phenanthrene moiety, which is a tricyclic aromatic compound with three non-linearly fused benzene.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Phenanthrenes and derivatives
Sub Class
Not Available
Direct Parent
Phenanthrenes and derivatives
Alternative Parents
Isoquinolones and derivatives / Tetralins / Coumarans / Anisoles / Alkyl aryl ethers / Aralkylamines / Piperidines / Tertiary alcohols / Trialkylamines / 1,2-aminoalcohols
show 7 more
Substituents
Phenanthrene / Isoquinolone / Tetralin / Coumaran / Anisole / Alkyl aryl ether / Aralkylamine / Piperidine / Cyclic alcohol / Tertiary alcohol
show 19 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
organic heteropentacyclic compound (CHEBI:7852)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Voltage-gated calcium channel activity
Specific Function
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone...
Gene Name
OPRM1
Uniprot ID
P35372
Uniprot Name
Mu-type opioid receptor
Molecular Weight
44778.855 Da
References
  1. Ordonez Gallego A, Gonzalez Baron M, Espinosa Arranz E: Oxycodone: a pharmacological and clinical review. Clin Transl Oncol. 2007 May;9(5):298-307. [PubMed:17525040]
  2. Riley J, Eisenberg E, Muller-Schwefe G, Drewes AM, Arendt-Nielsen L: Oxycodone: a review of its use in the management of pain. Curr Med Res Opin. 2008 Jan;24(1):175-92. [PubMed:18039433]
  3. Dietis N, Guerrini R, Calo G, Salvadori S, Rowbotham DJ, Lambert DG: Simultaneous targeting of multiple opioid receptors: a strategy to improve side-effect profile. Br J Anaesth. 2009 Jul;103(1):38-49. doi: 10.1093/bja/aep129. Epub 2009 May 27. [PubMed:19474215]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Opioid receptor activity
Specific Function
G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synt...
Gene Name
OPRK1
Uniprot ID
P41145
Uniprot Name
Kappa-type opioid receptor
Molecular Weight
42644.665 Da
References
  1. Ordonez Gallego A, Gonzalez Baron M, Espinosa Arranz E: Oxycodone: a pharmacological and clinical review. Clin Transl Oncol. 2007 May;9(5):298-307. [PubMed:17525040]
  2. Riley J, Eisenberg E, Muller-Schwefe G, Drewes AM, Arendt-Nielsen L: Oxycodone: a review of its use in the management of pain. Curr Med Res Opin. 2008 Jan;24(1):175-92. [PubMed:18039433]
  3. Nielsen CK, Ross FB, Lotfipour S, Saini KS, Edwards SR, Smith MT: Oxycodone and morphine have distinctly different pharmacological profiles: radioligand binding and behavioural studies in two rat models of neuropathic pain. Pain. 2007 Dec 5;132(3):289-300. Epub 2007 Apr 30. [PubMed:17467904]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Opioid receptor activity
Specific Function
G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine n...
Gene Name
OPRD1
Uniprot ID
P41143
Uniprot Name
Delta-type opioid receptor
Molecular Weight
40368.235 Da
References
  1. Ordonez Gallego A, Gonzalez Baron M, Espinosa Arranz E: Oxycodone: a pharmacological and clinical review. Clin Transl Oncol. 2007 May;9(5):298-307. [PubMed:17525040]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
4. Kappa-type opioid receptor 2b
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
References
  1. Smith MT: Differences between and combinations of opioids re-visited. Curr Opin Anaesthesiol. 2008 Oct;21(5):596-601. doi: 10.1097/ACO.0b013e32830a4c4a. [PubMed:18784485]
Kind
Protein group
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Not Available
Specific Function
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in...

Components:
References
  1. Leow KP, Wright AW, Cramond T, Smith MT: Determination of the serum protein binding of oxycodone and morphine using ultrafiltration. Ther Drug Monit. 1993 Oct;15(5):440-7. [PubMed:8249052]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Lalovic B, Phillips B, Risler LL, Howald W, Shen DD: Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos. 2004 Apr;32(4):447-54. [PubMed:15039299]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Lalovic B, Phillips B, Risler LL, Howald W, Shen DD: Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos. 2004 Apr;32(4):447-54. [PubMed:15039299]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Lalovic B, Phillips B, Risler LL, Howald W, Shen DD: Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos. 2004 Apr;32(4):447-54. [PubMed:15039299]

Drug created on June 13, 2005 07:24 / Updated on December 18, 2018 09:08